Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021

William B. B. Feldman,S. Sean Tu, Rasha Alhiary,Aaron S. S. Kesselheim,Olivier J. J. Wouters

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION（2023）

引用 5|浏览3

暂无评分

摘要

This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要